The British Association for Sexual Health and HIV UK guideline on the management of scabies has been updated in 2025. It provides details on the pathology and clinical features of scabies, with evidence-informed, practical recommendations on diagnosis, treatment and follow-up of adults and children aged 13 or above attending sexual health services. Key updates are detailed at the start of the article.
MellanbyKJohnsonCGBartleyWC, et al.Experiments on the survival and behaviour of the itch mite, sarcoptes scabiei DeG. Var. hominis. Bull Entom Res1942; 33(4): 267–271.
21.
SalavastruCMChosidowOBoffaMJ, et al.European guideline for the management of scabies. J Eur Acad Dermatol Venereol2017; 31: 1248–1253.
22.
ArlianLGRunyanRAAcharS, et al.Survival and infectivity of Sarcoptes scabiei var. canis and var. hominis. J Am Acad Dermatol1984; 11: 210–215.
23.
ChandlerDJFullerLC. A review of scabies: an infestation more than skin Deep. Dermatology2019; 235: 79–90.
24.
LiuJMWangHWChangFW, et al.The effects of climate factors on scabies. A 14-year population-based study in Taiwan. Parasite2016; 23: 54.
25.
MicaliGLacarrubbaFVerziAE, et al.Scabies: Advances in Noninvasive diagnosis. PLoS Negl Trop Dis2016; 10: e0004691.
26.
CinottiEPerrotJLLabeilleB, et al.Inefficacy of alcohol-based hand rub on mites in a patient with hyperkeratotic scabies. Clin Exp Dermatol2015; 40: 177–181.
27.
AndersenBMHaugenHRaschM, et al.Outbreak of scabies in Norwegian nursing homes and home care patients: control and prevention. J Hosp Infect2000; 45: 160–164.
28.
WaltonSFCurrieBJ. Problems in diagnosing scabies, a global disease in human and animal populations. Clin Microbiol Rev2007; 20: 268–279.
29.
KimHSHashimotoTFischerK, et al.Scabies itch: an update on neuroimmune interactions and novel targets. J Eur Acad Dermatol Venereol2021; 35: 1765–1776.
30.
FlindersDCDe SchweinitzP. Pediculosis and scabies. Am Fam Physician2004; 69: 341–348.
31.
SandersKMNattkemperLARosenJD, et al.Non-histaminergic itch Mediators elevated in the skin of a Porcine model of scabies and of human scabies patients. J Invest Dermatol2019; 139: 971–973.
32.
ChosidowO. Scabies and pediculosis. Lancet2000; 355: 819–826.
EngelmanDYoshizumiJHayRJ, et al.The 2020 international Alliance for the control of scabies consensus criteria for the diagnosis of scabies. Br J Dermatol2020; 183: 808–820.
37.
ShimoseLMunoz-PriceLS. Diagnosis, prevention, and treatment of scabies. Curr Infect Dis Rep2013; 15: 426–431.
38.
SunderkotterCFeldmeierHFolster-HolstR, et al.S1 guidelines on the diagnosis and treatment of scabies - short version. J Dtsch Dermatol Ges2016; 14: 1155–1167.
39.
WitkowskiJAParishLC. Scabies: a cause of generalized urticaria. Cutis1984; 33: 277–279.
40.
ChapelTAKrugelLChapelJ, et al.Scabies presenting as urticaria. JAMA1981; 246: 1440–1441.
41.
TesnerBWilliamsNOBrodellRT. The pathophysiologic basis of scabietic nodules. J Am Acad Dermatol2007; 57: S56–S57.
42.
KartonoFLeeEWLanumD, et al.Crusted Norwegian scabies in an adult with Langerhans cell histiocytosis: mishaps leading to systemic chemotherapy. Arch Dermatol2007; 143: 626–628.
43.
WongSSWooPCYuenKY. Unusual laboratory findings in a case of Norwegian scabies provided a clue to diagnosis. J Clin Microbiol2005; 43: 2542–2544.
44.
Talaga-CwiertniaInfestationKS. What is Already Known, and what is new about scabies at the Beginning of the third decade of the 21st Century?Pathogens2021; 10: 5.
45.
RobertsLJHuffamSEWaltonSF, et al.Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect2005; 50: 375–381.
46.
FalkESThorsbyE. HLA antigens in patients with scabies. Br J Dermatol1981; 104: 317–320.
47.
MorsyTARomiaSAal-GanayniGA, et al.Histocompatibility (HLA) antigens in Egyptians with two parasitic skin diseases (scabies and leishmaniasis). J Egypt Soc Parasitol1990; 20: 565–572.
48.
LinSFarberJLadoL. A case report of crusted scabies with methicillin-resistant Staphylococcus aureus bacteremia. J Am Geriatr Soc2009; 57: 1713–1714.
49.
ChinazzoMDesoubeauxGLeducqS, et al.Prevalence of nail scabies: a French Prospective multicenter study. J Pediatr2018; 197: 154–157.
50.
AroraPRudnickaLSar-PomianM, et al.Scabies: a comprehensive review and current perspectives. Dermatol Ther2020; 33: e13746.
51.
ThomasCCoatesSJEngelmanD, et al.Ectoparasites: scabies. J Am Acad Dermatol2020; 82: 533–548.
52.
DonabedianHKhazanU. Norwegian scabies in a patient with AIDS. Clin Infect Dis1992; 14: 162–164.
53.
InserraDWBickleyLK. Crusted scabies in acquired immunodeficiency syndrome. Int J Dermatol1990; 29: 287–289.
54.
CorbettELCrossleyIHoltonJ, et al.Crusted (“Norwegian”) scabies in a specialist HIV unit: successful use of ivermectin and failure to prevent nosocomial transmission. Genitourin Med1996; 72: 115–117.
55.
SchlesingerIOelrichDMTyringSK. Crusted (Norwegian) scabies in patients with AIDS: the range of clinical presentations. South Med J1994; 87: 352–356.
56.
OrkinM. Scabies in AIDS. Semin Dermatol1993; 12: 9–14.
57.
Fernandez-SanchezMSaeb-LimaMAlvarado-de la BarreraC, et al.Crusted scabies-associated immune reconstitution inflammatory syndrome. BMC Infect Dis2012; 12: 323.
58.
AydingozIEMansurAT. Canine scabies in humans: a case report and review of the literature. Dermatology2011; 223: 104–106.
59.
AdjeiOBrenyaRC. Secondary bacterial infection in Ghanaian patients with scabies. East Afr Med J1997; 74: 729–731.
60.
DiengMTNdiayeBNdiayeAM. Scabies complicated by acute glomerulonephritis in children: 114 cases observed in two years in a pediatric service in Dakar. Dakar Med1998; 43: 201–204.
61.
JarrettPSnowJ. Scabies presenting as a necrotizing vasculitis in the presence of lupus anticoagulant. Br J Dermatol1998; 139: 701–703.
62.
ValksRBuezoGFDaudenE. Scabies and leukocytoclastic vasculitis in an HIV-seropositive man. Int J Dermatol1996; 35: 605–606.
63.
ShinKJinHYouHS, et al.Clinical characteristics of pruritus in scabies. Indian J Dermatol Venereol Leprol2017; 83: 492–493.
64.
HanRTKimHYRyuH, et al.Glyoxal-induced exacerbation of pruritus and dermatitis is associated with staphylococcus aureus colonization in the skin of a rat model of atopic dermatitis. J Dermatol Sci2018; 90: 276–283.
65.
BlicharzLUsarekPMlynarczykG, et al.Is itch Intensity in atopic dermatitis associated with skin colonization by Staphylococcus aureus?Indian J Dermatol2020; 65: 17–21.
66.
MullerGJacobsPHMooreNE. Scraping for human scabies. A better method for positive preparations. Arch Dermatol1973; 107: 70.
67.
KatsumataKKatsumataK. Simple method of detecting sarcoptes scabiei var hominis mites among bedridden elderly patients suffering from severe scabies infestation using an adhesive-tape. Intern Med2006; 45: 857–859.
68.
MichelettiRGDominguezARWanatKA. Bedside diagnostics in dermatology: parasitic and noninfectious diseases. J Am Acad Dermatol2017; 77: 221–230.
69.
ChouelaEAbeldanoAPelleranoG, et al.Diagnosis and treatment of scabies: a practical guide. Am J Clin Dermatol2002; 3: 9–18.
70.
WalterBHeukelbachJFenglerG, et al.Comparison of dermoscopy, skin scraping, and the adhesive tape test for the diagnosis of scabies in a resource-poor setting. Arch Dermatol2011; 147: 468–473.
71.
BezoldGLangeMSchienerR, et al.Hidden scabies: diagnosis by polymerase chain reaction. Br J Dermatol2001; 144: 614–618.
72.
BanzhafCAThemstrupLRingHC, et al.In vivo Imaging of sarcoptes scabiei infestation using optical coherence tomography. Case Rep Dermatol2013; 5: 156–162.
73.
Chavez-AlvarezSVillarreal-MartinezAArgenzianoG, et al.Noodle pattern: a new dermoscopic pattern for crusted scabies (Norwegian scabies). J Eur Acad Dermatol Venereol2018; 32: e46–e47.
74.
KristjanssonAKSmithMKGouldJW, et al.Pink pigtails are a clue for the diagnosis of scabies. J Am Acad Dermatol2007; 57: 174–175.
75.
AussyAHouivetEHebertV, et al.Risk factors for treatment failure in scabies: a cohort study. Br J Dermatol2019; 180: 888–893.
76.
LeeyaphanCPluetrattanabhaNLimphokaP, et al.Scabicidal effect of heat on the in vitro survival of scabies mites and their eggs: optimal temperature and exposure time. Indian J Dermatol Venereol Leprol2019; 85: 647–649.
77.
BernigaudCFernandoDDLuH, et al.How to eliminate scabies parasites from fomites: a high-throughput ex vivo experimental study. JAAD. 2020; 83(1): 241–245. DOI:10.1016/j.jaad.2019.11.069.
NemecekRStockbauerALexaM, et al.Application errors associated with topical treatment of scabies: an observational study. J Dtsch Dermatol Ges2020; 18: 554–559.
80.
SunderkotterCAebischerANeufeldM, et al.Increase of scabies in Germany and development of resistant mites? Evidence and consequences. J Dtsch Dermatol Ges2019; 17: 15–23.
ChiuLWBergerTGChangAY. Management of common scabies and postscabetic itch in adults: Lessons learned from a single-center retrospective cohort study. Int J Womens Dermatol2021; 7: 716–720.
84.
RosumeckSNastADresslerC. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev2018; 4: CD012994.
85.
DhanaAYenHOkhovatJP, et al.Ivermectin versus permethrin in the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol2018; 78: 194–198.
86.
ThadaniponKAnothaisintaweeTRattanasiriS, et al.Efficacy and safety of antiscabietic agents: a systematic review and network meta-analysis of randomized controlled trials. J Am Acad Dermatol2019; 80: 1435–1444.
87.
GoldustMRezaeeEHemayatS. Treatment of scabies: comparison of permethrin 5% versus ivermectin. J Dermatol2012; 39: 545–547.
88.
Chitti BabuGKavita DharBPraveenA, et al.A comparative study to assess the efficacy of permethrin (topical) and benzyl benzoate (topical) for the treatment of scabies patients. IJPSR2019; 10: 3688–3693.
89.
ManjhiPKSinhaRIKumarM, et al.Comparative study of efficacy of oral ivermectin versus some topical antiscabies drugs in the treatment of scabies. J Clin Diagn Res2014; 8: HC01–HC04.
90.
Chitti BabuGKavita DharBPraveenA, et al.A comparative study to assess the efficacy of permethrin (topical) and ivermectin (oral) in scabies patients seeking care at a tertiary care teaching hospital of northern India. IJPSR2020; 11: 1155–1159.
91.
Abdel-RaheemTAMeabedEMNasefGA, et al.Efficacy, acceptability and cost effectiveness of four therapeutic agents for treatment of scabies. J Dermatolog Treat2016; 27: 473–479.
MbuagbawLSadeghiradBMorganRL, et al.Failure of scabies treatment: a systematic review and meta-analysis. Br J Dermatol2024; 190: 163–173.
94.
BachewarNPThawaniVRMaliSN, et al.Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol2009; 41: 9–14.
Ivermectin In: Joint Formulary Committee. British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain. https://bnf.nice.org.uk/drugs/ivermectin/ (accessed 15 April 2024).
97.
DuthalerULeisegangRKarlssonMO, et al.The effect of food on the pharmacokinetics of oral ivermectin. J Antimicrob Chemother2020; 75: 438–440.
98.
GuzzoCAFurtekCIPorrasAG, et al.Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol2002; 42: 1122–1133.
99.
MellonGHermetLToutainPL, et al.Scabies in an obese patient: How should the ivermectin dosing be adapted?Med Mal Infect2019; 49: 286–288.
100.
MeyersburgDKaiserABauerJW. Loss of efficacy of topical 5% permethrin for treating scabies: an Austrian single-center study. J Dermatolog Treat2022; 33: 774–777.
MeyersburgDWelponerTKaiserA, et al.Comparison of topical benzyl benzoate vs. oral ivermectin in treating scabies: a randomized study. J Eur Acad Dermatol Venereol2023; 37: 160–165.
105.
MeyersburgDHoellwerthMBrandlmaierM, et al.Comparison of topical permethrin 5% vs. benzyl benzoate 25% treatment in scabies: a double-blinded randomized controlled trial. Br J Dermatol2024; 190: 486–491.
ErtugrulGAktasH. Comparison of sulfur ointment and permethrin treatments in scabies. Dermatol Ther2022; 35: e15897.
108.
SeilerJCKeechRCAkerJL, et al.Spinosad at 0.9% in the treatment of scabies: efficacy results from 2 multicenter, randomized, double-blind, vehicle-controlled studies. J Am Acad Dermatol2022; 86: 97–103.
109.
DavisJSMcGloughlinSTongSY, et al.A novel clinical grading scale to guide the management of crusted scabies. PLoS Negl Trop Dis2013; 7: e2387.
110.
ThomasJCarsonCFPetersonGM, et al.Therapeutic potential of tea tree oil for scabies. Am J Trop Med Hyg2016; 94: 258–266.
111.
ThomasJDaveyRPetersonGM, et al.Treatment of scabies using a tea tree oil-based gel formulation in Australian Aboriginal children: protocol for a randomised controlled trial. BMJ Open2018; 8: e018507.
112.
MayPJTongSYCSteerAC, et al.Treatment, prevention and public health management of impetigo, scabies, crusted scabies and fungal skin infections in endemic populations: a systematic review. Trop Med Int Health2019; 24: 280–293.
113.
HuffamSECurrieBJ. Ivermectin for Sarcoptes scabiei hyperinfestation. Int J Infect Dis1998; 2: 152–154.
ChandlerRE. Serious neurological adverse events after ivermectin-do they occur beyond the indication of Onchocerciasis?Am J Trop Med Hyg2018; 98: 382–388.
117.
Alvarez-MorenoCCassellJADonkorCM, et al.Long-term consequences of the misuse of ivermectin data. Lancet Infect Dis2021; 21: 1624–1626.
ManjhiMYadavPMohanS, et al.A comparative study of topical tacrolimus and topical triamcinolone acetonide in nodular scabies. Dermatol Ther2020; 33: e13954.
120.
BernigaudCFischerKChosidowO. The management of scabies in the 21st Century: past, Advances and potentials. Acta Derm Venereol2020; 100: adv00112.
121.
DurandRBouvresseSBerdjaneZ, et al.Insecticide resistance in head lice: clinical, parasitological and genetic aspects. Clin Microbiol Infect2012; 18: 338–344.
122.
AbsilGLebasELibonF, et al.Scabies and therapeutic resistance: current knowledge and future perspectives. JEADV Clinical Practice2022; 1: 157–164.
123.
MounseyKEHoltDCMcCarthyJS, et al.Longitudinal evidence of increasing in vitro tolerance of scabies mites to ivermectin in scabies-endemic communities. Arch Dermatol2009; 145: 840–841.
124.
CurrieBJHarumalPMcKinnonM, et al.First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis2004; 39: e8–12.
125.
WaltonSFMyerscoughMRCurrieBJ. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg2000; 94: 92–96.
126.
MounseyKEHoltDCMcCarthyJ, et al.Scabies: molecular perspectives and therapeutic implications in the face of emerging drug resistance. Future Microbiol2008; 3: 57–66.
127.
PasayCArlianLMorganM, et al.High-resolution melt analysis for the detection of a mutation associated with permethrin resistance in a population of scabies mites. Med Vet Entomol2008; 22: 82–88.
128.
PasayCArlianLMorganM, et al.The effect of insecticide synergists on the response of scabies mites to pyrethroid acaricides. PLoS Negl Trop Dis2009; 3: e354.
129.
MounseyKEPasayCJArlianLG, et al.Increased transcription of Glutathione S-transferases in acaricide exposed scabies mites. Parasit Vectors2010; 3: 43.
130.
MounseyKEMcCarthyJSWaltonSF. Scratching the itch: new tools to advance understanding of scabies. Trends Parasitol2013; 29: 35–42.
131.
KhalilSAbbasOKibbiAG, et al.Scabies in the age of increasing drug resistance. PLoS Negl Trop Dis2017; 11: e0005920.
132.
TiplicaGSRadcliffeKEvansC, et al.2015 European guidelines for the management of partners of persons with sexually transmitted infections. J Eur Acad Dermatol Venereol2015; 29: 1251–1257.
133.
McCleanHRadcliffeKSullivanA, et al.2012 BASHH statement on partner notification for sexually transmissible infections. Int J STD AIDS2013; 24: 253–261.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
